Rochelle Bagatell

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Meredith S. Irwin, Arlene Naranjo, Fan F. Zhang et al. · Journal of Clinical Oncology · 2021 · 439 citations · Full text

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Shanu Modi, Alison Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2007 · 331 citations

Altered Hsp90 function in cancer: A unique therapeutic opportunity

Rochelle Bagatell, Luke Whitesell · Molecular Cancer Therapeutics · 2004 · 300 citations · Full text

Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.

Rochelle Bagatell, Gillian Paine-Murrieta, Charles W. Taylor et al. · PubMed · 2000 · 273 citations

Apoptosis, Cell Death, Cytotoxic Activity +17

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 268 citations · Full text

Cog Anbl1221, Neuro-oncology, Glioma +4